No joy foreseeable from Perrigo? Perrigo shares took a pounding Sunday on the Tel Aviv Stock Exchange, closing an arbitrage gap with Wall Street and losing more than 6% after Goldman Sachs advised investors to sell the stock on Friday. The New York investment bank also lowered its 12-month target for the dual-listed drug company from $117 to $110. Analyst Jami Rubin wrote that he sees "0%...